Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
37,871,761
-
Number of holders
-
39
-
Total 13F shares, excl. options
-
3,436,723
-
Shares change
-
+188,158
-
Total reported value, excl. options
-
$10,208,000
-
Value change
-
+$525,035
-
Put/Call ratio
-
77.8%
-
Number of buys
-
15
-
Number of sells
-
-12
-
Price
-
$2.97
Significant Holders of Anixa Biosciences Inc - Common Stock (ANIX) as of Q4 2021
46 filings reported holding ANIX - Anixa Biosciences Inc - Common Stock as of Q4 2021.
Anixa Biosciences Inc - Common Stock (ANIX) has 39 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3,436,723 shares
of 37,871,761 outstanding shares and own 9.07% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (1,307,811 shares), UBS Group AG (595,799 shares), RENAISSANCE TECHNOLOGIES LLC (330,800 shares), GEODE CAPITAL MANAGEMENT, LLC (263,951 shares), BlackRock Inc. (105,168 shares), Bank of New York Mellon Corp (98,652 shares), STATE STREET CORP (90,887 shares), NORTHERN TRUST CORP (60,229 shares), RAYMOND JAMES & ASSOCIATES (56,902 shares), and MORGAN STANLEY (54,542 shares).
This table shows the top 39 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.